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Huntington’s disease (HD) inclusions are stained with anti-ubiquitin and anti-proteasome antibodies. This, together with proteasome
activity studies on transfected cells, suggest that an impairment of the ubiquitin–proteasome system (UPS) may be key in HD pathogen-
esis. To test whether proteasome activity is impaired in vivo, we performed enzymatic assays for the three peptidase activities of the
proteasome in brain extracts from the HD94 conditional mouse model of HD. We found no inhibition of any of the activities, suggesting
that if UPS impairment happens in vivo, it is not at the level of the proteasome catalytic core. Intriguingly, the chymotrypsin- and
trypsin-like activities increased selectively in the affected and aggregate-containing regions: cortex and striatum. Western blot analysis
revealed no difference in total proteasome content whereas an increase in the interferon-inducible subunits of the immunoproteasome,
LMP2 and LMP7, was observed. These subunits confer to the proteasome catalytic properties that are optimal for MHC-I peptide
presentation. Immunohistochemistry in control mouse brain revealed LMP2 and LMP7 mainly in neurons. Accordingly, their increase in
HD94 mice predominantly took place in neurons, and 5% of the ubiquitin-positive cortical aggregates were also LMP2-positive. Ultra-
structural analysis of neurons with high level of immunoproteasome subunits revealed signs of neurodegeneration like nuclear inden-
tation or fragmentation and dark cell appearance. The neuronal induction of LMP2 and LMP7 and the associated signs of neurodegen-
eration were also found in HD postmortem brains. Our results indicate that LMP2 and LMP7 participate in normal neuronal physiology
and suggest a role in HD neurodegeneration.
Key words: Huntington’s disease; proteasome activity; immunoproteasome inducible subunits: LMP2, LMP7; conditional transgenic
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Introduction
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder caused by a CAG triplet repeat expansion
coding for a poly-glutamine (polyQ) sequence in the N-terminal
region of the huntingtin (htt) protein (Huntington’s Disease Col-
laborative Research Group, 1993). Patients suffer from motor
dysfunction, cognitive decline, and psychological disturbances
over 10 –15 years until death, caused by atrophy in the striatum
and the cortex (Ambrose et al., 1994).
At least eight other autosomal dominant neurological diseases
are also caused by a polyQ expansion mutation in their respective
proteins. These triplet-repeat disorders share an interesting com-
monality; the presence of intraneuronal aggregates containing
the expanded polyQ (Ross, 1997; Nakamura et al., 2001). These
aggregates have been found to be immunopositive for ubiquitin
and for proteasome subunits in HD and SCA-1 brains (DiFiglia et
al., 1997; Cummings et al., 1998) and in mouse and cell models of
most triplet-repeat disorders (Davies et al., 1997; Chai et al., 1999;
Stenoien et al., 1999; Martin-Aparicio et al., 2001).
The 20 S proteasome is a large cylindrical multisubunit mul-
ticatalytic proteinase that is involved in the degradation of most
cytosolic and nuclear proteins (Ciechanover and Schwartz, 1998;
Glickman and Ciechanover, 2002). Covalent attachment of a
poly-ubiquitin chain to a protein serves as a substrate targeting
and recognition signal for the proteasome (DeMartino and
Slaughter, 1999; Voges et al., 1999). Polyubiquitylated proteins
cannot be degraded directly by the 20 S proteasome. Rather, their
degradation requires the 19 S cap that binds to one or both ends
of the 20 S proteasome, unfolds substrate proteins, and induces a
conformational opening of the outer rings of the 20 S proteasome
(DeMartino and Slaughter, 1999).
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Sequestration of ubiquitylated proteins and of proteasome
subunits into polyQ-containing aggregates led to the hypothesis
that the activity of the ubiquitin-proteasome system (UPS) might
be impaired in CAG triplet-repeat disorders, thus resulting in
abnormal neuronal physiology and viability caused by altered
turnover of regulatory proteins by the proteasome. Evidence sup-
porting this hypothesis has been obtained in experiments per-
formed on transfected cells (Bence et al., 2001; Jana et al., 2001).
Additionally, we have previously reported that aggregates are dy-
namic structures that are cleared in vivo after shut down of
mutant-htt expression (Yamamoto et al., 2000) and that this
clearance is proteasomal-dependent (Martin-Aparicio et al.,
2001).
It is still not known the mechanism by which expanded polyQ
inhibits the UPS. This could be by saturating the capacity of one
or more chaperones required for UPS function (Bercovich et al.,
1997) or by direct interaction with the proteasome either at the
level of the catalytic core or at the level of recognition and unfold-
ing for presentation to the catalytic core.
To test whether the catalytic activity of the proteasome is in-
hibited in vivo, we performed assays for the three peptidase activ-
ities of the proteasome in HD94 mice. We found no inhibition of
any of the activities, thus ruling out a direct effect of the aggre-
gates on the 20 S proteasome. Conversely, we found an increase in
chymotrypsin- and trypsin-like activities that can be explained by
the also found neuronal increase of the inducible subunits of the
proteasome, LMP2 and LMP7. These subunits are selectively in-
duced in antigen-presenting cells, and the resulting proteasomes
exhibit altered catalytic characteristics that are optimal to gener-
ate peptides for MHC-I antigen presentation (Fruh et al., 1994).
The here reported expression and induction of LMP2 and LMP7
in neurons may offer new relevant clues to the role of the protea-
some in neuronal physiology and HD pathogenesis.
Materials and Methods
Animals
HD94 mice were generated as previously described (Yamamoto et al.,
2000). Mice were bred at the Centro de Biologı´a Molecular “Severo
Ochoa” (Madrid, Spain). Four to five mice were housed per cage with
food and water available ad libitum. Mice were maintained in a
temperature-controlled environment on a 12 hr light/dark cycle with
light onset at 7:00 A.M.
Antibodies
The following antibodies were used: anti-huntingtin N-terminal
CAG53b (amino acids 1–118 with 51 polyglutamines, a kind gift from
Dr. Wanker, Berlin, Germany), anti--tubulin (Sigma, St. Louis, MO),
anti--galactosidase (Promega, Madison, WI), anti-ubiquitin (Dako,
Carpinteria, CA), anti-poly-ubiquitinylated conjugates (FK-2) (Affinity
BioReagents, Golden, CO), monoclonal antibodies against 20 S protea-
some inducible  subunits: LMP2 (clone LMP2–13), LMP7 (clone
LMP7–1), polyclonal antibodies against 20 S proteasome  subunits:
LMP2 (PW8205), LMP7 (PW8200), MECL1 (PW8150), 2/MECL1
(PW8210), polyclonal antibody against 20 S proteasome subunits 1-7
(PW8195), monoclonal antibody against 20 S proteasome subunits 1
(PW 8140), polyclonal antibody against 20 S proteasome subunits 5
(PW 8895), and polyclonal antibodies against human 20 S proteasome
subunits LMP2 (PW8345), LMP7 (PW8355), and MECL1 (PW8350) (all
commercial anti-proteasome subunit antibodies were from Affinity). We
also used the fully characterized anti-proteasome polyclonal antibodies
raised against the proteasome multicatalytic protease (MPC) (Mengual
et al., 1996; Lafarga et al., 2002) and against the COOH-terminal region
of C2 subunit (Arribas et al., 1994; Lafarga et al., 2002).
Human samples
Brain specimens used in this study were removed at autopsy from three
HD (one woman aged 65 years and two men aged 71 and 68 years) and
three age-matched controls (one woman aged 80 years and two men aged
63 and 79 years) following the protocols of nervous tissue donation ap-
proved by the local Ethical Committees of the Barcelona and Bellvitge
brain banks. The postmortem delay in tissue processing was between 4
and 15 hr in both groups. The neuropathological examination in HD
cases revealed a diagnosis of HD grade 4 following the criteria of Vonsat-
tel et al. (1985), revised in Vonsattel and DiFiglia (1998).
Proteasome activity assays
Brain structures were placed on ice and homogenized in extraction buffer
(10 mM Tris-HCl, pH 7.8, 0.5 mM dithiothreitol, 5 mM ATP, 0.03%
Triton X-100, and 5 mM MgCl2). The lysates were centrifuged at
13,000 g at 4°C for 20 min. The resulting supernatants were placed on
ice and assayed for protein concentrations by the Bradford’s method
(Bio-Rad, Hercules, CA). For determination of proteasome activity, ex-
tracts were adjusted to 0.5 mg/ml total protein by dilution with extrac-
tion buffer. All assays were done in triplicate. Chymotrypsin-like activity
was determined using the substrate Suc-LLVY-aminomethylcoumarin
(AMC) (Sigma; 50 M), trypsin-like activity was determined using the
substrate Boc-LSTR-AMC (Sigma; 50 M), and post-glutamyl activity
was determined using the substrate Z-LLE--2-naphtylamine (Nap)
(Sigma; 0.2 mM). Assay mixtures containing 2 g of protein, substrate,
and 50 mM HEPES–KOH, pH 7.5, are made up in a final volume of 100
l. Incubations were performed at 37°C for 15 and 30 min. The cleavage
products AMC and Nap were analyzed, after stopping the reaction with 1
ml of 10% SDS in a fluorimeter (excitation/emission: 333/410 nm for
Nap and 380/460 nm for AMC). Product formation was linear with time
(at least for 60 min) and with protein concentration up to 4g of protein.
Background activity (caused by nonproteasomal degradation) was deter-
mined by addition of the proteasome inhibitor lactacystin at a final con-
centration of 50 M (Calbiochem, La Jolla, CA). To ensure maximal
content of aggregates, all proteasome activity experiments were per-
formed in aged HD94 mice (at least 1 year old) and age-matched control
mice.
Immunohistochemistry
Mouse brain. Mice were anesthetized with a xylazine– ketamine solution
and transcardially perfused with 4% paraformaldehyde (PFA) in Sorens-
en’s buffer for 10 min. Brains were postfixed in 4% PFA for 2 hr at 4°C
and cryoprotected in 30% sucrose solution. Thirty micrometer sagittal
sections were cut on a freezing microtome (Leica, Nussloch, Germany)
and collected in 0.1% azide-PBS solution. Next, brain sections were pre-
treated for 1 hr with 1% BSA, 5% FBS, and 0.2% Triton X-100 and then
incubated with primary antibodies at the following dilutions: monoclo-
nal anti-LMP2 (1:100), polyclonal LMP2 (1:1000), monoclonal anti-
LMP7 (1:100), polyclonal LMP7 (1:1000), monoclonal anti-MECL1 (1:
100), and anti-ubiquitin (1:500). Finally, brain sections were incubated
in avidin– biotin complex using the Elite Vectastain kit (Vector Labora-
tories, Burlingame, CA) Chromogen reactions were performed with dia-
minobenzidine (DAB; Sigma) and 0.003% H2O2 for 10 min. Sections
were coverslipped with Fluorosave.
Human brain. Samples (2-mm-thick) of the frontal cortex and stria-
tum that from control and HD subjects were fixed at the time of the
autopsy in 4% paraformaldehyde for 24 – 48 hr, and then immersed in
30% buffered saccharose for 48 hr. Once cryoprotected, the samples were
frozen and stored at 80°C until use. Then, 30 m sections were ob-
tained with a cryostat and processed for free-floating immunohisto-
chemistry in the same conditions as described for the mouse samples.
The primary antibodies assayed were the following: monoclonal anti-
LMP2 (1:100), polyclonal to human LMP2 (1:1000), monoclonal anti-
LMP7 (1:100), and polyclonal to human LMP7 (1:1000). Immunoreac-
tion was visualized with 0.05% DAB and 0.01% H2O2 (brown
precipitate). Immunohistochemistry plus TUNEL double-labeling was
conducted after a two-step protocol. First, the sections were processed
for immunohistochemistry, and the peroxidase reaction was visualized
with DAB and H2O2 (brown precipitate). Then, the sections were pro-
cessed for the method of in situ end-labeling of nuclear DNA fragmen-
tation with ApopTag: in situ apoptosis detection kit (Oncor, Gaithers-
burg, MD) following the instructions of the supplier with some
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modifications including omission of proteinase incubation. The reaction
was visualized with the nickel protocol (dark blue).
Quantification analysis from immunohistochemistry studies was per-
formed taking images from at least three different sections of indepen-
dent experiments using Axioskop 2 plus microscope and a CCD camera
(Coolsanp FX color). Positive signal was considered for the different
antibodies if the mean intensity value was 100 on a 0 –255 scale with
0 black and 255white. The cutoff value of 100 was determined from
visual analysis of inmunolabeling and by comparison with control (max-
imal level obtained with pre-absorbed antibodies).
Immunofluorescence studies
Sagittal mouse brain sections were pretreated with NH4Cl 50 mM, 1 M
glycine, 1% BSA, and 1% Triton X-100 in PBS buffer and incubated with
primary antibodies at the following dilutions: polyclonal anti-LMP2 (1:
1000) and monoclonal anti-ubiquitinylated conjugates (FK2) (1:10,000).
Subsequently, the brain sections were washed with PBS buffer and incu-
bated with secondary antibodies at the following dilutions: goat anti-
rabbit IgG labeled with Texas Red from Molecular Probes (Eugene, OR)
(1:400) and goat anti-mouse IgG labeled with Oregon Green 488 from
Molecular Probes (1:200). Finally, the brain sections were washed with
PBS and mounted following the standard procedures. Controls were
performed by following the same procedure but substituting the primary
antibodies by PBS in presence of 1% BSA.
Colocalization of two markers was analyzed by taking successive Ore-
gon green 488 and Texas Red fluorescent images using an Axioskop 2
plus microscope and a CCD camera (Coolsnap FX color). Positive signal
was considered for the different antibodies if the mean intensity value
was140 on a 0 –255 scale with 0 white and 255 black. The cutoff
value of 140 was determined from visual analysis of immunolabeling and
by comparison with control (maximal level obtained with preabsorbed
antibodies).
Tissue processing for electron microscopy
For electron microscopy, vibratome sections were used. Once immuno-
stained as above described, the sections were postfixed in 2% OsO4 for 1
hr, dehydrated, embedded in araldite, and flat-mounted in Formvar-
coated slides, using plastic coverslips. After polymerization, selected ar-
eas were photographed, trimmed, re-embedded in araldite, and resec-
tioned at 1 m. These semithin sections were re-photographed and
resectioned in ultrathin sections. The ultrathin sections were observed in
a Jeol electron microscope, without heavy metal staining to avoid arti-
factual precipitates.
Western blot analysis
Mouse samples. Extracts for Western blot analysis were prepared by ho-
mogenizing fresh dissected mouse brain regions in ice-cold extraction
buffer consisting of 20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM NaF, 1%
Triton X-100, 1 mM sodium orthovanadate, 10 mM EDTA, and protease
inhibitors (2 mM PMSF, 10g/ml aprotinin, 10g/ml leupeptin, and 10
g/ml pepstatin). The samples were homogenized at 4°C, and protein
content was determined by Bradford assay. Total protein (20 g) was
electrophoresed on 10% SDS-PAGE gel and transferred to a nitrocellu-
lose membrane (Schleicher & Schuell, Keene, NH). The experiments
were performed using the following primary antibodies: anti-whole pro-
teasome (MCP, 1:1000), anti-C2-c-terminal (1:1000), anti--tubulin (1:
20,000), monoclonal anti-LMP2 (1:500), monoclonal anti-LMP7
(1:500), polyclonal anti-LMP7 (1:10,000), monoclonal anti-MECL1 (1:
500), polyclonal anti-5 (1:500), and monoclonal anti-1 (1:500). The
filters were incubated with the antibody at 4°C overnight in 5% nonfat
dried milk. A secondary goat anti-mouse (monoclonal antibodies) or
goat anti-rabbit (polyclonal antibodies) antibody (both 1:5000; Invitro-
gen, Gaithersburg, MD) was used followed by ECL detection (Amer-
sham, Arlington Heights, IL).
Human samples. Fresh samples of the frontal cortex and striatum were
obtained at the time of the autopsy, and they were immediately frozen on
dry ice and stored at 80°C for biochemical studies. Control and HD
brain samples were processed following the same protocol as described
for mouse samples.
Quantification of immunoreactivity was performed by using a GS-710
Calibrated Imaging densitometer scanner controller by Quantity One PC
software from Bio-Rad. In all cases, the average intensity value of the
pixels in a background selected region was calculated and was subtracted
from each pixel in the samples. The densitometry values obtained in the
linear range of detection with these antibodies were normalized with
respect to the values obtained with an anti--tubulin antibody to correct
for any deviation in loaded amounts of protein. Statistical analysis was
performed using one-way ANOVA followed by Bonferroni test.
Results
Increased chymotrypsin- and trypsin-like proteasome
activities in cortex and striatum of HD94 mice
HD94 mice express exon 1 htt with a 94 polyQ repeat in the
forebrain (under control of the CamKIIa promoter) in a tetracy-
cline regulated manner (Yamamoto et al., 2000). As previously
shown, HD94 mice develop intraneuronal aggregates that can be
detected in cortex and striatum with anti N-terminal (e.g.,
CAG53b) and anti-ubiquitin antibodies (Yamamoto et al., 2000;
Martin-Aparicio et al., 2001) (Fig. 1A). To test whether the pres-
ence of intraneuronal aggregates results in impaired proteasomal
activity in vivo, we assayed the chymotrypsin-like, the trypsin-
like, and the post-glutamyl peptidase activities of the proteasome
in cortical and striatal homogenates from HD94 mice and from
control littermates (Fig. 1B). The proteasome activities were also
assayed in cerebellum as a control brain region devoid of aggre-
gates (Fig. 1A). On the contrary to what was expected, we found
significantly increased chymotrypsin- and trypsin-like protea-
some activities in the cortex and striatum of HD94 mice, whereas
no differences were found in the cerebellum. In the case of the
post-glutamyl activity, no difference was found between HD94
and control mice in any of the analyzed brain regions (Fig. 1B).
Figure 1. Increased chymotrypsin-like and trypsin-like proteasome activities in aggregate
containing brain regions of the HD94 mice. A, Immunohistochemistry with anti-N-terminal htt
(CAG53b) or anti-ubiquitin antibodies revealed the presence of aggregates in the cortex and the
striatum, but not in the cerebellum, of HD94 mice. Both nuclear (empty arrows) and neuropil
aggregates (black arrows) can be detected. Cx, Cortex; St, striatum; Cb, cerebellum; ML, molec-
ular layer; PCL, Purkinje cell layer; GCL, granule cell layer. Scale bar, 20 m. B, The
chymotrypsin-like, trypsin-like, and post-glutamyl peptidase activities of the proteasome were
assayed in brain extracts of control and HD94 mice by incubating with fluorogenic substrates as
described in Materials and Methods. The chymotrypsin-like and trypsin-like activities (shown in
arbitrary units) were significantly (*p0.01) increased in the cortex and striatum of HD94 mice
with respect to control littermates.
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Increased levels of the inducible subunits of the
immunoproteasomes LMP2 and LMP7 in HD94 mice
In view of the unexpected increase in two of the proteasome
catalytic activities, we reasoned that a possible explanation could
be that the UPS is actually impaired in neurons harboring aggre-
gates and that these neurons have a higher content of protea-
somes as an attempt to counteract their decreased activity. To test
this possibility, we performed Western blot analysis with differ-
ent anti-proteasome antibodies (Fig. 2). The polyclonal anti-
MCP antibody raised against native 20 S proteasome (Mengual et
al., 1996) revealed no difference in proteasome content between
HD94 and control mice neither in cortex (Fig 2A) nor in the
striatum (data not shown). Similar results were obtained with the
1–7 antibody that recognizes six of the seven -subunits of the
20 S proteasome. We therefore concluded that the increase in
chymotrypsin- and trypsin-like proteasome activities is not at-
tributable to an increase in proteasome steady-state levels, as
could have been anticipated by the fact that the post-glutamyl
activity did not increased in parallel.
We next explored possible qualitative changes in the protea-
some that might account for an increase in some of the catalytic
activities. Because truncation of the C2 (6) subunit has been
shown to result in activation of proteasome catalytic activity (Ar-
ribas et al., 1994), we performed Western blot with an affinity-
purified antibody directed against the C2 COOH- terminal that is
able to discriminate the active and latent forms of the protea-
some. These experiments revealed no difference either in the elec-
trophoretic motility or in the level of C2 (Fig. 2A).
Another possible explanation for a qualitative change in the
proteasome that could account for increased catalytic activity,
and more precisely, of the chymotrypsin- and trypsin-like activ-
ities, was the upregulation of the inducible  subunits LMP2,
LMP7, and MECL-1. These are catalytic  subunits that are up-
regulated in antigen-presenting cells in response to various stim-
uli (like IFN or TNF-), and that replace the constitutive 
catalytic subunits (1, 2, and 5) of the proteasomes (Tanaka
and Kasahara, 1998; Kloetzel, 2001; Rock et al., 2002). The result-
ing proteasomes are called immunoproteasomes and display al-
tered catalytic activities (chymotrypsin- and trypsin-like activi-
ties selectively increased) that are optimal for MHC class I epitope
processing (Tanaka and Kasahara, 1998; Kloetzel, 2001; Rock et
al., 2002). Despite the very low expression of MHC in the brain,
consistent with the notion that the brain is an immunologically
privileged organ (Xiao and Link, 1998), and the previously re-
ported low levels of subunits LMP2, LMP7, and MECL-1 in brain
compared with other tissues (Noda et al., 2000), we decided to
analyze by Western blot whether their levels were altered in HD94
mice. As shown in Figure 2B, both LMP2 and LMP7 levels were
significantly increased in the cortex (52.3 and 43.2%, respec-
tively; *p 0.01) and the striatum (53.1 and 41.1%, respectively;
*p  0.01) of 14-month-old HD94 mice, whereas no changes
were found in the cerebellum (data not shown). No significant
changes were found in the level of MECL-1 in any of the analyzed
brain regions (data not shown). We then analyzed if the increase
in LMP2 and LMP7 subunits also takes place in the brain of mice
younger than those used for the proteasome activity assays. As
shown in Figure 2C, no change in the level of these subunits was
found in 3-month-old mice despite the presence of aggregates
(Martin-Aparicio et al., 2001). In 7-month-old mice, only LMP7
levels were found increased (32.9%; *p 0.01) in the cortex but
not in the striatum of HD94 mice, despite substantial striatal
atrophy (Yamamoto et al., 2000). Induction of immunoprotea-
some subunits thus seems to happen in the brain of HD94 mice
only after marked neuropathology has developed. Western blot
analysis with specific anti-1 and anti-5 subunit antibodies re-
vealed that the increase in LMP2 and LMP7 subunits was not
accompanied by a concomitant decrease in the corresponding
constitutive  subunits (data not shown).
The induction of the immunoproteasome subunits in HD94
mice takes place in neurons
We next performed immunohistochemistry experiments to in-
vestigate the cell types in which the induction of the immunopro-
teasomal subunits takes place (Fig. 3). Interestingly, staining with
the LMP2–13 monoclonal antibody in the brain of control mice
revealed that the most prominent LMP2 immunoreactivity was
localized in neurons, and this was the case in most analyzed brain
regions (Fig. 3A shows LMP2 staining in pyramidal neurons of
the cortex, for example). This staining was specific because this
immunoreactivity was not observed when primary antibody was
omitted or when a nonrelevant monoclonal antibody was used.
Apart from neuronal cells, some astrocytes could also be de-
tected, particularly in white matter areas (data not shown). In
HD94 mouse brains, the increase in LMP2 immunostaining was
found also in neurons and most remarkably in cortical pyramidal
cells (Fig. 3B–D). Despite the fact that increased LMP2 levels were
also found in the striatum of HD94 mice by Western blot (Fig. 2),
no evident staining of cell bodies was detected in the striatum
(data not shown), thus suggesting that the increase in LMP-2
resides in the observed neuropil staining and most likely in cor-
ticostriatal projections. Similar results regarding the neuronal
pattern and the increased staining in cortical pyramidal neurons
were obtained with the LMP7–1 monoclonal anti LMP-7 anti-
body (Fig. 3D) (data not shown).
A subset of ubiquitin-positive aggregates in the brain of
HD94 mice contain LMP2
Interestingly, immunohistochemistry with a polyclonal anti-
LMP2 antibody (Fig. 3C), apart from confirming the neuronal
identity of the cells harboring the increase in LMP2, also revealed
aggregates in the cortex of HD94 mice similar in shape to those
Figure 2. Increased levels of the interferon-inducible subunits of the immunoproteasomes
LMP2 and LMP7 in cortex and striatum of HD94 mice. A, Western blot analysis of brain cortical
extracts of HD94 mice (HD94) and control littermates ( C) with the MCP antibody (raised against
native 20 S proteasome), the1-7 antibody (that recognizes six of the seven-subunits of
the 20 S proteasome), and the C2 (6) antibody (raised against the C2 COOH- terminal region
and that is able to discriminate the active and latent forms of the proteasome). Membranes are
probed with an anti-tubulin antibody to correct for any possible deviation on protein loading. B,
Western blot analysis of brain cortical (Cx) and striatal (St) extracts from 14-month-old HD94
mice and control littermates with antibodies against the LMP2 and LMP7 inducible subunits of
the immunoproteasome. Membranes are probed with an anti-tubulin antibody to correct for
any possible deviation on protein loading. C, Histograms showing the densitometric quantifi-
cation of LMP2 and LMP7 levels in HD94 versus control samples in 3-, 7-, and 14-month-old
mice (*p 0.01).
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detected with anti-ubiquitin antibodies (although they were less
frequent). We then performed double immunofluorescence
studies to determine if LMP2-positive aggregates are a subset of
the ubiquitin-positive aggregates or if they are an independent
population of inclusions. As shown in Figure 3E–I, all LMP2-
immunopositive aggregates were also ubiquitin-positive, but
they represented only 5% of the total of ubiquitin-positive
aggregates.
The induction of LMP2 occurs in degenerating neurons
Immunoelectron microscopy with LMP2 antibodies confirmed
the neuronal identity of stained cells in the cortex of either con-
trol (Fig. 4A) or HD94 mice (Fig. 4B,C). The staining, as previ-
ously detected by light microscopy, was mainly diffuse cytoplas-
mic, but the ultrastructural analysis also revealed scattered
immunoreactive patches within the nucleus, cytoplasm, and
vacuoles of most labeled neurons.
Interestingly, all cortical neurons that at the ultrastructural
level showed features of degeneration such as nuclear indentation
(Fig. 4B) even close to nuclear fragmentation (Fig. 4B) or dark
appearance (Fig. 4C) showed a positive LMP2 inmunolabeling.
Increased levels of LMP2 and LMP7 in cortex and striatum of
HD patients
We then decided to test whether the induction of the immuno-
proteasome subunits observed in the mouse model of HD also
took place in brains of HD patients. We analyzed the level of
LMP2 and LMP7 by Western blot in cortex and striatum of grade
4 HD patients and age-matched controls. As shown in Figure 5,
the level of LMP2 was 80% higher in the cortex of HD brains than
in control brains ( p  0.01) and 150% higher in the striatum
( p  0.01). Regarding LMP7, the increase was even of higher
magnitude both in the cortex (500%; p 0.005) and the striatum
(350%; p 0.005) respect to the controls. Western blot analysis
with specific anti-1 and anti-5 subunit antibodies revealed
that the increase in LMP2 and LMP7 subunits was accompanied
by a concomitant decrease in the corresponding constitutive 
subunits in the striatum (76.6 6.5%, p 0.01 in the case of the
1 subunit and 56.3  2.5%, p  0.01 in the case of the 5
subunit). However, no change was found in the cortex regarding
the level of these constitutive  subunits.
The induction of the immunoproteasome in HD brains also
takes place in degenerating neurons
Immunohistochemistry in the cortex of human control subjects
and of HD patients with anti-LMP2 (Fig. 6A,B) and anti-LMP7
(Fig. 6C,D) antibodies yielded very similar results to those found
in the mouse model. The neuronal pattern in control samples was
even more evident in the human cortex both with LMP2 (Fig.
6A) and LMP7 (Fig. 6C) antibodies. There was also a marked
increase in LMP2 and LMP7 immunoreactivity in cortical neu-
rons of HD brains and, in good agreement with the Western blot
data, the increase respect to the control samples was higher than
the one found in the mouse model (Fig. 6B,D,I).
In the striatum of HD patients, on the contrary to what was
described before regarding the mouse model, some LMP2-
Figure 3. LMP2 is present in neurons and increases in neurons of HD94 mice in which it can
be found in ubiquitinated inclusions. Cortical sections from 14-month-old control ( A), or HD94
mice (B, C, E–I ). Cortical pyramidal neurons are revealed by immunohistochemistry with the
(LMP2–13) LMP2 monoclonal antibody in control mice ( A), and this neuronal staining is mark-
edly increased in HD94 mice (B, D). C, The LMP2 polyclonal antibody confirmed the neuronal
staining and also revealed LMP2-positive aggregates in the cortex of HD94 mice similar in shape
(both ovoid, empty arrows, and spheroid, black arrows) to those detected with anti-ubiquitin
antibodies. D, Histogram showing the number of LMP2- or LMP7-immunoreactive (IR) cells in
the cortex of control and HD94 mice. E–I, Double immunofluorescence with anti-polyubiquitin
(FK-2 antibody) and LMP2 polyclonal antibodies of HD94 cortical sections. E shows the abun-
dance of ubiquitin-positive aggregates in a low-magnification image of the cortex of HD94
mice. White arrowheads in F–I show that a subset of ubiquitin-positive aggregates (F, H ) are also
LMP2-positive (G, I ). Scale bars: (in B) A, B, 50m; C, 25m; (in E), E, 200m; F–I, 50m.
Figure 4. HD94 cortical neurons with heightened levels of LMP2 show signs of neurodegen-
eration. Immunoelectronmicroscopy images of control ( A) or HD94 (B, C) sections stained with
LMP2. A, Neuron with cytoplasmic LMP2 staining in the cortex of a control mouse. B, Nuclear
indentations (empty arrows) in an HD94 cortical LMP2-positive neuron. C, LMP2-positive dark neuron
in the cortex of an HD94 mouse. Black arrows, Patches of reaction product. Scale bar, 1m.
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immunoreactive neurons could be found (Fig. 6G,H). Interest-
ingly, some of these neurons were also TUNEL-positive (Fig.
6H). Regarding LMP7 immunostaining in the human striatum, a
faint staining could be detected in the somas of some medium size
spiny neurons in control samples (Fig. 6E). The intensity and the
number of labeled neurons markedly increased in the striatum of
HD cases (Fig. 6F,J).
Immunoelectron microscopy in the human samples (Fig. 7)
once again confirmed the neuronal identity of LMP2- and LMP7-
labeled cells. The ultrastructural analysis also revealed that corti-
cal pyramidal neurons of HD cases with increased LMP2 and
LMP7 staining present nuclear indentation similar to what was
described for the mouse model (Fig. 7B) (data not shown).
Discussion
In this study, by performing proteasome activity assays in brain
extracts from the HD94 conditional mouse model of HD (that
contain polyQ and ubiquitin-positive aggregates), we have found
that the 20 S proteasome activity is not decreased when compared
with extracts from control mice. On the contrary, two of the
proteolytic activities of the proteasome were increased in the ex-
tracts from HD94 mice without a change in total proteasome
content. These data revealed a qualitative change in HD94 pro-
teasomes that can be explained by an increase in the level of
inducible subunits of the immunoproteasomes LMP2 and LMP7.
Because we found that this increase mainly takes place in neurons
and that those neurons show signs of neurodegeneration, our
data suggest a role of the immunoproteasome in normal neuro-
nal physiology as well as in HD pathogenesis.
The initial aim of this study was to test if, as suggested by
studies on transfected cells (Bence et al., 2001; Jana et al., 2001),
the UPS is impaired in vivo in a mouse model of HD. The HD94
mice we used here (Yamamoto et al., 2000) express exon 1 mu-
tant huntingtin under control of the CamKII promoter (that
drives expression to forebrain neurons) leading to aggregate for-
mation in cortical and striatal neurons (the brain areas affected in
HD). If we had gotten the expected result of decreased 20 S pro-
Figure 5. Increased levels of LMP2 and LMP7 in cortex and striatum of HD patients. A,
Protein extracts were prepared from cortical and striatal postmortem samples of control and HD
cases, resolved by SDS-PAGE, and immunoblotted with anti-LMP2, anti-LMP7, and anti--
tubulin antibodies. B, Histograms showing the densitometric quantification of the increase in
LMP2 and LMP7 in HD versus control samples (*p 0.01; **p 0.005).
Figure 6. The increase in LMP2 and LMP7 in HD brains takes place in neurons and correlates
with TUNEL staining in the striatum. A–D, Cortical section from control (A, C) or HD brains (B, D)
stained with anti-LMP2 (A, B) or anti-LMP7 (C, D) antibodies. E, F, LMP7 immunohistochemistry
in the striatum of a control ( E) or HD case ( F). Arrows indicate medium-size spiny neurons with
faint (black arrows) or strong (empty arrows) LMP7 staining. G, LMP2-immunostained
medium-sized spiny neuron in the striatum of an HD case. H, LMP2 and TUNEL double-labeled
medium-size spiny neuron in the striatum of an HD case. I, Histogram showing the number of
LMP2- or LMP7-immunoreactive (IR) cells in the cortex of control and HD brains. J, Histogram
showing the number of LMP2- or LMP7-immunoreactive cells in the striatum of control and HD
brains. Scale bars: (in D) A–D, 40m; (in F ) E, F, 50m; (in H ) G, H, 10m.
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teasome peptidase activity in the aggregate-containing brain ex-
tracts, we would have assumed that an impairment of the UPS
occurs in vivo in the aggregate-containing neurons of the mouse
model. However, we did not detect decreased proteasome activity
in the cell extracts (in fact we got the opposite result in the case of
the chymotrypsin- and trypsin-like activities and no change in
the case of the post-glutamyl activity). Therefore, our results
strongly suggest that the proteasome peptidase activity is not
inhibited in the neurons of the HD94 mice by the presence of
aggregates. However, because we are measuring total proteasome
activities not only for aggregate-containing neurons, but also in
non-aggregate-containing neurons and other cell types such as
glia, the possibility still exists that proteasome activity is de-
creased in some aggregate-containing neurons and that more
numerous neurons without aggregates and or glial cells have in-
creased proteasome activity, averaging a final increased protea-
some activity for the whole cellular population.
Our data, despite suggesting that a decrease in 20 S protea-
some activity does not happen in HD94 neurons, cannot rule out
that impairment of the UPS does take place in the brain of HD94
mice at a level different than 20 S proteasome intrinsic catalytic
activity. The reason for this is that small fluorogenic substrates
are degraded by the 20 S proteasome in a ubiquitination-
independent manner. Therefore, these assays can detect alter-
ations in the catalytic activity of the 20 S proteasome, but will fail
to detect, alterations at any other level of the UPS such as avail-
ability of free ubiquitin, polyubiquitilation, recognition by the
19S proteasome, and or unfolding and presentation to the 20 S
proteasomes.
Therefore, to elucidate whether the UPS is impaired in vivo, a
different approach will be required (Herna´ndez et al., 2004). Such
an approach could be the generation of mice with neuronal ex-
pression of a reporter protein with a tag for efficient degradation
by the UPS (like the GFPu used in the cell transfection experi-
ments (Bence et al., 2001). We are currently generating this type
of mice. Interestingly, very recently, UPS reporter mice have been
generated that express a different type of UPS reporter substrate
(Ub-G76V-GFP) (Lindsten et al., 2003).
There is a discrepancy between the studies reporting de-
creased proteasome activity with fluorogenic substrates in trans-
fected (Bence et al., 2001; Jana et al., 2001) or infected (Nishitoh
et al., 2002) cells that express expanded polyQ-containing pro-
teins, and our data from the mouse model. The most plausible
explanation for this is that the level of expression of the patho-
genic protein within the transfected or infected cell is much
higher that in the transgenic tissue. The level of expression ob-
tained in the transgenic tissue is supposed to be less artifactual
because it is high enough to elicit neuronal neuropathology and
symptomatology in adult mice, but low enough not to cause
premature and artifactual death of the neurons expressing the
pathogenic protein. Because we have performed the studies on
aggregate-containing extracts from symptomatic mice, our data
probably reflect better the situation in the affected neurons in an
HD patient. In this regard, there is another report of transfected
cells expressing GFP with expanded polyQ sequences, in which
no inhibition of proteasome activity could be detected with flu-
orogenic substrates (Ding et al., 2002). Interestingly, this study
was performed in stably transfected SH-SY5Y cells that probably
elicit lower levels of expression of the foreign protein (as evi-
denced by the lack of aggregate formation) in comparison to the
conditionally overexpressing N2A Tet-Off transfected cells (Jana
et al., 2001) or the infected primary neurons (Nishitoh et al.,
2002).
Regarding the mechanism by which expression of mutant htt
results in increased levels of LMP2 and LMP7, it is possible that
the UPS could actually be impaired in vivo in the HD94 mice and
that the induction of the immunoproteasome subunits would be
a compensatory action of the affected neurons trying to counter-
act the decreased clearance of proteins. Other possibilities regard-
ing the mechanism by which expression of mutant htt results in
increased levels of LMP2 and LMP7 are: (1) that these genes
(located in the MHC genome region and that usually show a
parallel transcriptional regulation (Beck and Trowsdale, 1999)
are part of the alterations in gene transcription elicited by the
expression of toxic polyQ-containing proteins. If this is the case,
an increase in LMP2 and LMP7 would be expected in other CAG
triplet repeat disorders, (2) that neurons produce LMP2 and
LMP7 expression in response to proinflammatory cytokines
Figure 7. Ultrastructural analysis of LMP7-positive neurons from the cortex of HD patients.
Immunoelectronmicroscopy images of cortical section from control ( A) or HD human samples
( B) stained with LMP7. A, Neuron with cytoplasmic LMP7 staining in the cortex of control
subject. B, Nuclear indentations (empty arrows) in LMP7-positive cortical neurons from HD
cases. Black arrows, Patches of reaction product. Arrowheads, Lipofuscin accumulations. Scale
bar, 1m.
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(such as IFN) released by reactive glia, similarly to what happens
in lymphocytes and other antigen-presenting cells. In this regard,
we have previously shown that HD94 mice have reactive gliosis in
striatum and cortex (Yamamoto et al., 2000) and we have shown
here the expression of LMP2 by satellite glia adjacent to LMP2-
positive neurons. If the induction of LMP2 and LMP7 were sec-
ondary to neuroinflammation, as a corollary, it would be ex-
pected to happen also in another neurodegenerative diseases with
a marked reactive gliosis such as Alzheimer’s disease (Akiyama et
al., 2000) and in related animal models with a strong gliosis (Lu-
cas et al., 2001; Herna´ndez et al., 2002). We are currently explor-
ing these possibilities.
The correlation between heightened levels of LMP2 and
LMP7 and signs of neurodegeneration suggests that the induc-
tion of the immunoproteasome might have pathogenic implica-
tions. However, it is also possible that the neurodegeneration is
secondary to neuroinflammatory stress, and the induction of the
immunoproteasome subunits could just be a marker of neurons
degenerating by this mechanism. This is supported by the obser-
vation that LMP2 and LMP7 induction takes place only after
substantial neuropathology has developed in HD94 brains and by
the fact that decreased level of constitutive 1 and 5 subunits is
observed only in the striatum (the most affected region) of grade
4 HD human brains. In any case, it cannot be ruled out that
altered proteolytic processing of proteasome substrates (because
of the altered proteolytic activities) might also contribute to the
toxicity elicited by expanded polyQ in advanced stages of the
disease.
Regarding the possible implications of the induction of the
interferon-inducible subunits of the immunoproteasome, be-
cause these confer to the proteasomes catalytic properties that are
optimal to generate peptides for MHC-I antigen presentation, it
would be interesting to explore if the levels of MHC-I molecules
are also altered in HD. Many of the genes participating in MHC-I
antigen presentation are located within the MHC genome region
and show parallel transcriptional regulation (Beck and Trows-
dale, 1999). Furthermore, it has been suggested that MHC-I may
participate in neuronal plasticity (Boulanger et al., 2001), and
neuronal induction of MHC-I has been shown to happen only in
electrically silent neurons, thus suggesting a possible implication
in immunosurveillance on functionally impaired neurons (Neu-
mann et al., 1995).
In summary, the data presented here, apart from revealing a
role of the immunoproteasome in normal neuronal physiology,
bring new light on the status of the UPS in vivo in HD and offer
new clues about the intraneuronal changes that may contribute
to the neuronal dysfunction and eventual neuronal death that are
responsible for HD symptomatology.
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